Equillium Banner Image


  • Ticker EQ
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Equillium Logo Image
  • 11-50 Employees
  • Based in San Diego, California
Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products for autoimmune and inflammatory disorders, or immuno-inflammation, with high unmet medical need. Their initial product candidate, EQ001, is a first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cellMore activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis. They believe EQ001 may have broad therapeutic utility and their current pipeline is focused on developing EQ001 as a best-in-class treatment for multiple severe immuno-inflammatory disorders.
4.8 / 5.0 (214)

Equillium reports have an aggregate usefulness score of 4.8 based on 214 reviews.


Most Recent Annual Report

MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Equillium Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!